Michael H. Davidson, chief executive officer and director of NewAmsterdam Pharma Co N.V. (NASDAQ: NAMS), purchased 10,000 ordinary shares on Sept. 14, 2026, at $22.65 per share, according to a Form 4 filing with the U.S. Securities and Exchange Commission.

Following the transaction, Davidson directly holds 792,923 ordinary shares, which includes 163,352 shares subject to restricted stock unit awards that remain subject to vesting. The filing also notes a prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by Davidson, which had been held by Stichting Administratiekantoor EPNAP for his benefit.

Davidson also indirectly holds 285,715 ordinary shares through the Michael H. Davidson 2026 Grantor Retained Annuity Trust, for which he serves as the sole annuitant and trustee.